Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01358162 · ClinicalTrials.gov registry record · Phase 1
Phase IC Study of Safety and PK of SQ109 300mg Daily
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT01358162 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 10 participants.
The verdict
NCT01358162, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
Healthy male and female volunteers will be given SQ109 300mg daily for 14 days to assess the safety and tolerability and pharmacokinetics.
Interventions
- OTHER Placebo
- DRUG SQ109
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01358162
The ClinicalTrials.gov registry entry for NCT01358162 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01358162 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01358162 about?
NCT01358162 is a clinical study titled "Phase IC Study of Safety and PK of SQ109 300mg Daily". Healthy male and female volunteers will be given SQ109 300mg daily for 14 days to assess the safety and tolerability and pharmacokinetics.
What is the current status of trial NCT01358162?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2010-11. Estimated completion is 2011-04.
What interventions are being tested in trial NCT01358162?
The interventions under investigation include: Placebo (OTHER), SQ109 (DRUG).
Who is sponsoring clinical trial NCT01358162?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.